Literature DB >> 9104730

Disease activity, cumulative damage and quality of life in systematic lupus erythematosus: results of a cross-sectional study.

J G Hanly1.   

Abstract

The relationship between disease activity, cumulative damage and self-reported quality of life was examined in 96 patients with Systematic Lupus Erythematosus (SLE). Disease activity was measured by the SLE Disease Activity Index (SLEDAI) and cumulative damage by the Systematic Lupus International Cooperating Clinics/ACR damage index (DI). Quality of life was assessed by the Medical Outcomes Survey Short Form 20 (SF-20) self-report questionnaire which consists of six subscales. The study population was predominantly Caucasian (91%) and female (90%). The mean (+/- s.d.) age was 42.0 +/- 11.0 years and disease duration was 7.5 +/- 5.5 years. SLEDAI scores varied from 0-28, with a mean (+/- s.d.) of 4.8 +/- 5.2. The mean (+/- s.d.) DI score was 0.74 +/- 1.06, with a range of 0-5. Subscales of the SF-20 varied from 0-100 and the range of mean (+/- s.d.) scores varied from 35.0 +/- 42.2 to 70.5 +/- 28.7. There was no correlation between SLEDAI and DI scores or between SLEDAI scores and any of the six subscales of the SF-20. Likewise there was no correlation between DI scores and SF-20 subscales with the exception of Health perception (r = 0.34, P = 0.02). These results indicate that there are at least three independent dimensions of health status in SLE, namely disease activity, cumulative damage and quality of life. Furthermore, the extent of inflammatory disease activity and irreversible target organ damage are not the sole determinants for quality of life in SLE patients.

Entities:  

Mesh:

Year:  1997        PMID: 9104730     DOI: 10.1177/096120339700600305

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  16 in total

1.  The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus.

Authors:  Joerg Albrecht; Lynne Taylor; Jesse A Berlin; Samuel Dulay; Gina Ang; Steven Fakharzadeh; Jonathan Kantor; Ellen Kim; Giuseppe Militello; Karen McGinnis; Stephen Richardson; James Treat; Carmela Vittorio; Abby Van Voorhees; Victoria P Werth
Journal:  J Invest Dermatol       Date:  2005-11       Impact factor: 8.551

2.  Validation of the Pediatric Automated Neuropsychological Assessment Metrics in childhood-onset systemic lupus erythematosus.

Authors:  Hermine I Brunner; Marisa S Klein-Gitelman; Frank Zelko; Erin C Thomas; Jessica Hummel; Shannen M Nelson; Jennifer Huggins; Megan L Curran; Tresa Roebuck-Spencer; Dean W Beebe; Jun Ying
Journal:  Arthritis Care Res (Hoboken)       Date:  2013-03       Impact factor: 4.794

3.  Development and initial validation of a self-assessed lupus organ damage instrument.

Authors:  Karen H Costenbader; Munther Khamashta; Silvia Ruiz-Garcia; Maria Teresa Perez-Rodriguez; Michelle Petri; Jennifer Elliott; Susan Manzi; Elizabeth W Karlson; Tabitha Turner-Stokes; Bonnie Bermas; Jonathan Coblyn; Elena Massarotti; Peter Schur; Patricia Fraser; Iris Navarro; John G Hanly; Timothy S Shaver; Robert S Katz; Eliza Chakravarty; Paul R Fortin; Martha L Sanchez; Jigna Liu; Kaleb Michaud; Graciela S Alarcón; Frederick Wolfe
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-04       Impact factor: 4.794

Review 4.  Quality-of-life measurements versus disease activity in systemic lupus erythematosus.

Authors:  Adnan N Kiani; Michelle Petri
Journal:  Curr Rheumatol Rep       Date:  2010-08       Impact factor: 4.592

5.  Quality of life of women with systemic lupus erythematosus or rheumatoid arthritis: domains of importance and dissatisfaction.

Authors:  B Archenholtz; C S Burckhardt; K Segesten
Journal:  Qual Life Res       Date:  1999-08       Impact factor: 4.147

6.  Health-related quality of life in patients with systemic lupus erythematosus: development and validation of a lupus specific symptom checklist.

Authors:  C Grootscholten; G Ligtenberg; R H W M Derksen; K M G Schreurs; J W de Glas-Vos; E C Hagen; A W L van den Wall Bake; T W J Huizinga; F H J van den Hoogen; M Bijl; J C van Houwelingen; F J Snoek; J H M Berden
Journal:  Qual Life Res       Date:  2003-09       Impact factor: 4.147

Review 7.  Patient-Reported Outcomes in Systemic Lupus Erythematosus.

Authors:  Mary Mahieu; Susan Yount; Rosalind Ramsey-Goldman
Journal:  Rheum Dis Clin North Am       Date:  2016-03-17       Impact factor: 2.670

8.  Predictors of self-reported health-related quality of life in systemic lupus erythematosus.

Authors:  Adnan N Kiani; Vibeke Strand; Hong Fang; Jawali Jaranilla; Michelle Petri
Journal:  Rheumatology (Oxford)       Date:  2013-05-16       Impact factor: 7.580

Review 9.  The socioeconomic burden of SLE.

Authors:  Chak Sing Lau; Anselm Mak
Journal:  Nat Rev Rheumatol       Date:  2009-06-09       Impact factor: 20.543

10.  The frequency and outcome of lupus nephritis: results from an international inception cohort study.

Authors:  John G Hanly; Aidan G O'Keeffe; Li Su; Murray B Urowitz; Juanita Romero-Diaz; Caroline Gordon; Sang-Cheol Bae; Sasha Bernatsky; Ann E Clarke; Daniel J Wallace; Joan T Merrill; David A Isenberg; Anisur Rahman; Ellen M Ginzler; Paul Fortin; Dafna D Gladman; Jorge Sanchez-Guerrero; Michelle Petri; Ian N Bruce; Mary Anne Dooley; Rosalind Ramsey-Goldman; Cynthia Aranow; Graciela S Alarcón; Barri J Fessler; Kristjan Steinsson; Ola Nived; Gunnar K Sturfelt; Susan Manzi; Munther A Khamashta; Ronald F van Vollenhoven; Asad A Zoma; Manuel Ramos-Casals; Guillermo Ruiz-Irastorza; S Sam Lim; Thomas Stoll; Murat Inanc; Kenneth C Kalunian; Diane L Kamen; Peter Maddison; Christine A Peschken; Soren Jacobsen; Anca Askanase; Chris Theriault; Kara Thompson; Vernon Farewell
Journal:  Rheumatology (Oxford)       Date:  2015-09-05       Impact factor: 7.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.